Condensed Consolidated Financial Statements Detail (Tables)

3 Months Ended

Mar. 31, 2015

Condensed Consolidated Financial Statements Detail [Abstract]

Outstanding securities considered anti-dilutive

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

	March 31,
	2015		2014
Common stock options and restricted stock units		8,756		5,732
Warrants for common stock		20,690		1,910
Total		29,446		7,642

Reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock

For the three months ended March 31, 2015 and 2014, the following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):

	Three Months Ended March 31,
	2015			2014
Numerator
Net loss
Basic	$	(21,718	)	$	(4,687	)
Adjustment for revaluation of contingent warrant liabilities		-			(19,534	)
Diluted	$	(21,718	)	$	(24,221	)
Denominator
Weighted average shares outstanding used for basic net loss per share		116,193			106,158
Effect of dilutive warrants		-			9,366
Weighted average shares outstanding and dilutive securities used for diluted net loss per share		116,193			115,524

Accrued liabilities

Accrued and other liabilities consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):

	March 31, 2015		December 31, 2014
Accrued payroll and other benefits	$	2,578	$	3,061
Accrued management incentive compensation		1,149		4,295
Accrued clinical trial costs		1,079		1,424
Other		1,186		1,112
Total	$	5,992	$	9,892